UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views ...

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna's Evernorth unit said in an announcement that pharmacies participating in EnReachRx will offer both 30-day and 90-day prescriptions for GLP-1s based on the patient's coverage. Patients will ...

Evernorth’s initial program, called EncircleRx, launched early 2024 and has since ramped to cover 9 million patients, Cigna executives said on a Friday morning call with investors. Now ...